Research programme: tuberculosis therapies - GPC Biotech
Alternative Names: AX 20017; TBT1 tuberculosis series - GPC Biotech; TBT3 tuberculosis series - GPC BiotechLatest Information Update: 23 Jan 2007
At a glance
- Originator GPC Biotech AG
- Class
- Mechanism of Action Protein kinase G inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 01 Jun 2005 The tuberculosis programme is available for licensing (http://www.gpc-biotech.com)
- 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
- 12 Nov 2004 Preclinical trials in Tuberculosis in Switzerland (unspecified route)